Draxis to buy Ivax manufacturing site
Draxis Health has entered into a memorandum of agreement with Ivax to acquire that firm's Kirkland, Quebec, pharmaceutical manufacturing facility. The 238,000-sq-ft facility will serve as the permanent site for Draxis Health's radiopharmaceutical
Draxis Health has entered into a memorandum of agreement with Ivax to acquire that firm's Kirkland, Quebec, pharmaceutical manufacturing facility. The 238,000-sq-ft facility will serve as the permanent site for Draxis Health's radiopharmaceutical subsidiary, Draximage, which announced plans for growth in February (SCAN 2/18/98).
The facility, whose sterile manufacturing department produces prescription pharmaceuticals for the U.S. and Canadian marketplace, is also expected to assume manufacturing responsibilities for the Mississauga, Ontario-based company's SpectroPharm Dermatology product line, as well as Anipryl, the firm's veterinary drug that was recently licensed to Pfizer Animal Health. The acquisition of the facility was expected to close in late March.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
